Molecular Biology Reports, Год журнала: 2024, Номер 51(1)
Опубликована: Июль 20, 2024
Язык: Английский
Molecular Biology Reports, Год журнала: 2024, Номер 51(1)
Опубликована: Июль 20, 2024
Язык: Английский
Pathology - Research and Practice, Год журнала: 2023, Номер 252, С. 154949 - 154949
Опубликована: Ноя. 18, 2023
Язык: Английский
Процитировано
13Pathology - Research and Practice, Год журнала: 2024, Номер 253, С. 155087 - 155087
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
4Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155023 - 155023
Опубликована: Дек. 10, 2023
Язык: Английский
Процитировано
10Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155044 - 155044
Опубликована: Дек. 20, 2023
Язык: Английский
Процитировано
10Cancers, Год журнала: 2024, Номер 16(5), С. 1033 - 1033
Опубликована: Март 2, 2024
Multiple myeloma (MM) is the second most common hematologic malignancy in world and accounts for 15% of primary hemocytopathies, with an ever-increasing number new cases. It asymptomatic 30% instances; hence, determination highly sensitive specific markers necessary to make a proper diagnosis. In last 20 years, miRNAs, involved regulating expression genes responsible cell proliferation differentiation, including tumor cells, have been identified as potential diagnostic prognostic markers. The main aim following review was outline role miRNAs diagnosis prognosis MM, considering their pathogenesis disease identifying target pathways. For this purpose, publications dating from 2013–2023 reviewed. Based on available data, it concluded that non-coding RNAs could be MM. Furthermore, they may serve therapeutic targets certain drugs.
Язык: Английский
Процитировано
3Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155027 - 155027
Опубликована: Дек. 11, 2023
Язык: Английский
Процитировано
8Heliyon, Год журнала: 2024, Номер 10(7), С. e28167 - e28167
Опубликована: Март 21, 2024
Cancer remains a challenging disease worldwide, necessitating innovative approaches to better comprehend its underlying molecular mechanisms and devise effective therapeutic strategies. Over the past decade, microRNAs (miRNAs) have emerged as crucial players in cancer progression due their regulatory roles various cellular processes. Moreover, involvement of unwanted soluble receptors has gained increasing attention because they contribute tumorigenesis or drug resistance by disrupting normal signaling pathways neutralizing ligands. This comprehensive review explores intricate interplay between miRNAs unwanted-soluble context biology. study provides an analysis interactions these receptors, elucidating how can either suppress enhance expression. MiRNAs directly target receptor transcripts, thereby regulating levels. They also modulate proteolytic cleavage membrane-bound into forms targeting sheddases, such ADAMs MMPs. Furthermore, delves potential manipulating receptors. Various strategies, including synthetic miRNA mimics anti-miRNAs, hold promise for restoring inhibiting function counteract aberrant activity. exploring miRNA-based delivery systems may provide targeted precise therapies that minimizing off-target effects. In conclusion, this sheds light on networks involving biology uncovering novel targets, paving way developing anti-cancer therapies.
Язык: Английский
Процитировано
2Experimental Cell Research, Год журнала: 2024, Номер 442(2), С. 114279 - 114279
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
2Pathology - Research and Practice, Год журнала: 2023, Номер 253, С. 155054 - 155054
Опубликована: Дек. 22, 2023
Язык: Английский
Процитировано
6Pathology - Research and Practice, Год журнала: 2024, Номер 253, С. 155085 - 155085
Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
1